Skip to main content
Top
Published in: Clinical and Translational Oncology 3/2017

Open Access 01-03-2017 | Research Article

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

Authors: J. Salvador, J. A. Urtasun, F. J. B. Duart, R. García-Campelo, R. G. Carbonero, P. Lianes, A. Llombart, D. I. Casado, J. M. Piera, M. M. Mateu, J. Puente, F. Rivera, C. A. Rodríguez, J. A. Virizuela, M. Martín, P. Garrido

Published in: Clinical and Translational Oncology | Issue 3/2017

Login to get access

Abstract

Purpose

The Spanish Society of Medical Oncology (SEOM) has conducted a study on the access to oncologic drugs across the 17 Spanish Regions with the aim of identifying potential heterogeneities and making proposals for eliminating the barriers identified at the different levels.

Methods

An Expert Panel made up of medical oncologists designed a survey on certain indications approved for 11 drugs in the approach of breast cancer, melanoma, lung cancer, prostate cancer and support treatment. This survey was sent to 144 National Health System (NHS) hospitals.

Results

77 hospitals answered the survey. The information modules analysed were: scope of the Commission that establishes binding decisions related to drug access; conditions, stages and periods of drug application, approval and administration processes; barriers to accessing drugs.

Conclusions

The study shows variability in drug access. The SEOM makes proposals addressed to reducing the differences identified and homogenizing drug access conditions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stewart BW, Wild CP, editors. World Cancer Report 2014. The International Agency for Research on Cancer (IARC). 2014. Stewart BW, Wild CP, editors. World Cancer Report 2014. The International Agency for Research on Cancer (IARC). 2014.
2.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed 14 Dec 2015. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr. Accessed 14 Dec 2015.
3.
go back to reference Galcerán J, Ameijide A, Carulla M, Mateos A, Quirós JR, Alemán A, et al. Estimaciones de la incidencia y la supervivencia del cáncer en España y su situación en Europa. Red Española de Registros de Cáncer (REDECAN), 2014. Galcerán J, Ameijide A, Carulla M, Mateos A, Quirós JR, Alemán A, et al. Estimaciones de la incidencia y la supervivencia del cáncer en España y su situación en Europa. Red Española de Registros de Cáncer (REDECAN), 2014.
4.
go back to reference Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol. 2015;33(7):786–809.CrossRefPubMed Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol. 2015;33(7):786–809.CrossRefPubMed
8.
go back to reference IMS Institute for Healthcare Informatics. Developments in cancer treatments, market dynamics, patient access and value. Global Oncolog Trend Report 2015. 2015. IMS Institute for Healthcare Informatics. Developments in cancer treatments, market dynamics, patient access and value. Global Oncolog Trend Report 2015. 2015.
12.
go back to reference Bergmann L, Enzmann H, Thirstrup S, Schweim JK, Widera I, Zwierzina H. Access to innovative oncology medicines in Europe. Ann Oncol. 2016;27(2):353–6.CrossRefPubMed Bergmann L, Enzmann H, Thirstrup S, Schweim JK, Widera I, Zwierzina H. Access to innovative oncology medicines in Europe. Ann Oncol. 2016;27(2):353–6.CrossRefPubMed
13.
go back to reference Puigventós Latorre F, Santos-Ramos B, Ortega Eslava A, Durán-García ME; Grupo de Evaluación de Novedades, Estandarización e Investigación en Selección de Medicamentos (GENESIS) de la Sociedad Española de Farmacia Hospitalaria (SEFH). Variabilidad en la actividad y los resultados de la evaluación de nuevos medicamentos por las comisiones de farmacia y terapéutica de los hospitales en España. Farm Hosp. 2011;35(6):305–14. Puigventós Latorre F, Santos-Ramos B, Ortega Eslava A, Durán-García ME; Grupo de Evaluación de Novedades, Estandarización e Investigación en Selección de Medicamentos (GENESIS) de la Sociedad Española de Farmacia Hospitalaria (SEFH). Variabilidad en la actividad y los resultados de la evaluación de nuevos medicamentos por las comisiones de farmacia y terapéutica de los hospitales en España. Farm Hosp. 2011;35(6):305–14.
14.
go back to reference Panteli D, Eckhardt H, Nolting A, Busse R, Kulig M. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Res Policy Syst. 2015;2015(13):39.CrossRef Panteli D, Eckhardt H, Nolting A, Busse R, Kulig M. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Res Policy Syst. 2015;2015(13):39.CrossRef
15.
go back to reference Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71.CrossRefPubMed Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71.CrossRefPubMed
Metadata
Title
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions
Authors
J. Salvador
J. A. Urtasun
F. J. B. Duart
R. García-Campelo
R. G. Carbonero
P. Lianes
A. Llombart
D. I. Casado
J. M. Piera
M. M. Mateu
J. Puente
F. Rivera
C. A. Rodríguez
J. A. Virizuela
M. Martín
P. Garrido
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 3/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1535-8

Other articles of this Issue 3/2017

Clinical and Translational Oncology 3/2017 Go to the issue

Acknowledgement to Reviewers

Thanks to reviewers

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine